Received Mar 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Iost a lot of weight; lack of appetite; lack of sleep; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of weight loss in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (recived 1st dose on an unknown date). On 11-JUN-2024, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced weight loss (Verbatim: Iost a lot of weight), appetite absent (Verbatim: lack of appetite) and sleep loss (Verbatim: lack of sleep). The outcome of the weight loss, appetite absent and sleep loss were not reported. It was unknown if the reporter considered the weight loss, appetite absent and sleep loss to be related to Shingrix. It was unknown if the company considered the weight loss, appetite absent and sleep loss to be related to Shingrix. Additional Information: GSK receipt date: 01-FEB-2024 This case was reported by a patient via interactive digital media. The patient said he/she suffered severe side effects after the second dose of the vaccine that sent them to the emergency room. The patient experienced weight loss, lack of appetite and sleep. The patient reported that he/she had been at least 6times in the emergency department of different hospitals.